Loading...
Loading...
All product recalls associated with MOMO TEA INC.
Total Recalls
1000
Past Year
1000
Class I (Serious)
145
Most Recent
Jan 2026
Data from FDA, USDA, CPSC, and NHTSA public records. Recall counts vary by company size, industry, and reporting practices. Always check official sources for current information.
Product does not declare the allergen, milk, on the label.
Subpotent
Subpotent
Subpotent
Subpotent
Pumps may experience Wireless Connection Modules intermittent connection alarms, which will interrupt an active infusion. Interruption or delay of therapy can lead to serious patient injury or death.
There is a potential for thermal damage in CADD-Solis and CADD- Solis VIP infusion pumps.
Affected pumps may trigger an erroneous (false) Upstream Occlusion Alarm under certain conditions, which will interrupt an active infusion. Interruption or delay of therapy can lead to serious patient injury or death.
Patient monitor has nine identified cybersecurity vulnerabilities.
Four (4) total reports were sent to customers with clinically relevant variants requiring amendment, one (1) of which with an incorrect negative CDx claim. The remaining three (3) with tumor profiling result changes did not impact CDx indications.
Three is the potential for the retractors to puncture through the sterile packaging.
The high voltage capacitor may fail early in the product life cycle after delivery of surge voltages. When this failure occurs, the capacitor may produce smoke and a burning smell. In extremely rare instances a capacitor may cause a spark or excessive heat when an internal capacitor failure occurs.
Due to a software issue, the software may incorrectly process the date of birth (DoB) received from the Laboratory Information System (LIS) and when the DoB is set to 01/01/1900 or left empty, REMISOL Advance may incorrectly identify a patient as a newborn, affecting the execution of validation rules based on incorrect reference ranges. The test results are not changed by this software defect and are accurately displayed by REMISOL Advance; however, the evaluation flagging of the results may be affected. This issue may lead to wrong reference range calculations and can result in erroneous flagged results being auto validated and uploaded to LIS.
Firm's product, Creamy Butter Sauce, was manufactured with recalled ingredient (Cilantro) which contained small wood like pieces.
A cybersecurity vulnerability was discovered through internal testing.
Vials of implant bone granules may contain less product then specified on labeling.
A cybersecurity vulnerability was discovered through internal testing.
Disconnection of the adapter from the endotracheal tube can potentially be difficult or not possible.
Potential for internal fastening mechanism within generator of mobile x-Ray to fail.
Potential for microbial contamination.